Drug Trial Radar · NCT07523217
Poly-L-Lactic Acid in Atrophic Acne Scars
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Mar 15, 2026
Primary completion
Mar 15, 2027
Study completion Mar 15, 2027
Sponsor
- Lead sponsor
- Zagazig UniversityGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: Management of atrophic acne scars remains challenging due to their heterogeneous morphology and suboptimal response to conventional therapies. Poly-L-lactic acid (PLLA), a biostimulatory agent, promotes neocollagenesis and has emerged as a promising therapeutic option. However, comparative data on different delivery modalities of PLLA and their effects on dermal remodeling and skin physiology remain limited. Objective: To compare two delivery modalities of PLLA (injectable versus mono-thread) and evaluate their effects on dermal remodeling, clinical outcomes, and safety in atrophic acne scars. Methods: This prospective split-face study included 24 patients with atrophic acne scars. The right facial side was treated with a single session of PLLA mono-threads, while the left side received two sessions of injectable PLLA at 6-week intervals. Clinical outcomes were assessed using Goodman and Baron's qualitative and quantitative grading systems over a 3-month follow-up period.
Conditions
- Atrophic Acne Scarring
Interventions
injectable PLLADrug
The vial was reconstituted with 8 mL of bacteriostatic sterile water for injection (BSWFI). After at least 2 hours, 2 mL of lidocaine (1-2%) with epinephrine was added, making the total solution volume 10 mL. One hour later, the vial was gently shaken, and the syringes were prepared for injection. The injection was given using 28-G needles beneath each scar with a serial injection technique during each session.
PLLA threadsDrug
On the right side of the face, PLLA threads were used in a single session. Approximately 8-10 Everline PLLA mono-threads
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in Goodman and Baron's qualitative grading scoreTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zagazig University Hospitals
Zagazig, Sharqia Province, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.